The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection
Open accessAbstract
Emerging reports of rare neurological complications associated with COVID-19 infection and vaccinations are leading to regulatory, clinical and public health concerns. We undertook a self-controlled case series study to investigate hospital admissions from neurological complications in the 28 days after a first dose of ChAdOx1nCoV-19 (n = 20,417,752) or BNT162b2 (n = 12,134,782), and after a SARS-CoV-2-positive test (n = 2,005,280). There was an increased risk of Guillain–Barré syndrome (incidence rate ratio (IRR), 2.90; 95% confidence interval (CI): 2.15–3.92 at 15–21 days after vaccination) and Bell’s palsy (IRR, 1.29; 95% CI: 1.08–1.56 at 15–21 days) with ChAdOx1nCoV-19. There was an increased risk of hemorrhagic stroke (IRR, 1.38; 95% CI: 1.12–1.71 at 15–21 days) with BNT162b2. An independent Scottish cohort provided further support for the association between ChAdOx1nCoV and Guillain–Barré syndrome (IRR, 2.32; 95% CI: 1.08–5.02 at 1–28 days). There was a substantially higher risk of all neurological outcomes in the 28 days after a positive SARS-CoV-2 test including Guillain–Barré syndrome (IRR, 5.25; 95% CI: 3.00–9.18). Overall, we estimated 38 excess cases of Guillain–Barré syndrome per 10 million people receiving ChAdOx1nCoV-19 and 145 excess cases per 10 million people after a positive SARS-CoV-2 test. In summary, although we find an increased risk of neurological complications in those who received COVID-19 vaccines, the risk of these complications is greater following a positive SARS-CoV-2 test.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Overall, studies of the vector-based vaccines such as the ChAdOx1, have observed a higher incidence of GBS after vaccination compared with the background incidence; whereas, most studies of the mRNA vaccines, such as BNT162b2 and mRNA-1273, have not observed in creases of GBS [14,15,24 -27].”
From COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals (2024) · cites this paper as [27]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Patone et al. [27] reported 38 excess cases of GBS per 10 million exposed in the 1 -28 days risk period following vaccination with ChAdOx1 in England.”
The cited source says what the claim attributes to it.
In the citing paper
“Among self-controlled case series, one reported a rate ratio of 1.38 (95 % CI 1.12-1.71) for hemorrhagic stroke following Pfizer vaccine, [26] another reported 0.97 (95 % CI 0.81-1.15), [27] while a cohort study[28] reported 0.84 (95 % CI 0.54-1.27).”
From Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults (2022) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527
Negative Controls: A Tool for Detecting Confounding and Bias in Observational Studies
Lipsitch, M., Tchetgen Tchetgen, E., & Cohen, T. (2010) · Epidemiology · doi:10.1097/ede.0b013e3181d61eeb · Cited by 1,583
Lopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., et al. (2021) · BMJ · doi:10.1136/bmj.n1088 · Cited by 1,389
Self-citationVaratharaj, A., Thomas, N., Ellul, M. A., Davies, N. W. S., Pollak, T. A., Tenorio, E. L., Sultan, M., Easton, A., Breen, G., Zandi, M., et al. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(20)30287-x · Cited by 1,246
The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings
Paterson, R. W., Brown, R. L., Benjamin, L., Nortley, R., Wiethoff, S., Bharucha, T., Jayaseelan, D. L., Kumar, G., Raftopoulos, R. E., Zambreanu, L., et al. (2020) · Brain · doi:10.1093/brain/awaa240 · Cited by 1,124
Menni, C., Klaser, K., May, A., Polidori, L., Capdevila, J., Louca, P., Sudre, C. H., Nguyen, L. H., Drew, D. A., Merino, J., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00224-3 · Cited by 1,031
Vasileiou, E., Simpson, C. R., Shi, T., Kerr, S., Agrawal, U., Akbari, A., Bedston, S., Beggs, J., Bradley, D., Chuter, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00677-2 · Cited by 549
Self-citationSelf controlled case series methods: an alternative to standard epidemiological study designs
Petersen, I., Douglas, I., & Whitaker, H. (2016) · BMJ · doi:10.1136/bmj.i4515 · Cited by 525
Pottegård, A., Lund, L. C., Karlstad, Ø., Dahl, J., Andersen, M., Hallas, J., Lidegaard, Ø., Tapia, G., Gulseth, H. L., Ruiz, P. L.-D., et al. (2021) · BMJ · doi:10.1136/bmj.n1114 · Cited by 401
Cited by
Ndeupen, S., Qin, Z., Jacobsen, S., Bouteau, A., Estanbouli, H., & Igyártó, B. Z. (2021) · iScience · doi:10.1016/j.isci.2021.103479 · Cited by 678
Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis
Trougakos, I. P., Terpos, E., Alexopoulos, H., Politou, M., Paraskevis, D., Scorilas, A., Kastritis, E., Andreakos, E., & Dimopoulos, M. A. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.04.007 · Cited by 273
Guillain‐Barré syndrome: a comprehensive review
Bellanti, R., & Rinaldi, S. (2024) · European Journal of Neurology · doi:10.1111/ene.16365 · Cited by 246
van Doorn, P. A., Van den Bergh, P. Y. K., Hadden, R. D. M., Avau, B., Vankrunkelsven, P., Attarian, S., Blomkwist‐Markens, P. H., Cornblath, D. R., Goedee, H. S., Harbo, T., et al. (2023) · European Journal of Neurology · doi:10.1111/ene.16073 · Cited by 235
Fraiman, J., Erviti, J., Jones, M., Greenland, S., Whelan, P., Kaplan, R. M., & Doshi, P. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.08.036 · Cited by 228
“71) for hemorrhagic stroke following Pfizer vaccine, [26] another reported 0.”
Background
Metadata
- Authors
- Patone, M., Handunnetthi, L., Saatci, D., Pan, J., Katikireddi, S. V., Razvi, S., Hunt, D., Mei, X. W., Dixon, S., Zaccardi, F., Khunti, K., Watkinson, P., Coupland, C. A. C., Doidge, J., Harrison, D. A., Ravanan, R., Sheikh, A., Robertson, C., & Hippisley-Cox, J.
- Affiliations
- University of Oxford (GB)
- Centre for Human Genetics (GB)
- University of Strathclyde (GB)
- MRC/CSO Social and Public Health Sciences Unit (GB)
- University of Glasgow (GB)
- UK Dementia Research Institute (GB)
- University of Leicester (GB)
- University of Nottingham (GB)
- London School of Hygiene & Tropical Medicine (GB)
- ORCID
- Patone, Martina
- Handunnetthi, Lahiru
- Saatci, Defne
- Pan, Jiafeng
- Katikireddi, Srinivasa Vittal
- Razvi, Saif
- Hunt, David
- Mei, Xue W.
- Dixon, Sharon
- Zaccardi, Francesco
- Khunti, Kamlesh
- Watkinson, Peter
- Coupland, Carol A. C.
- Doidge, James
- Harrison, David A.
- Ravanan, Rommel
- Sheikh, Aziz
- Robertson, Chris
- Hippisley-Cox, Julia
- Venue
- Nature Medicine
- Published
- 2021-10-25
- Volume
- 27
- Issue
- 12
- Pages
- 2144-2153
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC8629105
- OpenAlex
- W3210722677
- Cited by
- 394
- References
- 25
- Citations by year
- 2026: 27 · 2025: 38 · 2024: 77 · 2023: 89 · 2022: 155 · 2021: 8
- FWCI
- 26.03
- Type
- journal article
- Language
- en
- Update notices
- correction (2021-11-29)
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Edinburgh Research Explorer (University of Edinburgh) (acceptedVersion, cc-by)
- Strathprints: The University of Strathclyde institutional repository (University of Strathclyde) (acceptedVersion)
- Repository@Nottingham (University of Nottingham) (submittedVersion, cc-by)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion, cc-by)
- Funders
- U.S. Department of Veterans Affairs (PEC 13‐001)
- Wellcome Trust (215621/Z/19/Z)
- UK Research and Innovation (SCAF/15/02, MC_UU_00022/2, MC_PC_20029)
- Cancer Research UK (A18085, C5255, C5255/A18085, 204826/Z/16/Z)
- National Institute for Health and Care Research (CL-2019-13-001, 13001, MC_UU_00022/2, C5255/A18085, SCAF/15/02)
- Academy of Medical Sciences (AMS-SGCL7-Hunt)
- University of Oxford (204826/Z/16/Z)
- Medical Research Council (MC_UU_00022/2, SPHSU17, MC_UU_00022, MC_PC_20029, SCAF/15/02)
- Health Data Research UK (MC_PC_20029)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Clinical Neurology › Long-Term Effects of COVID-19
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- COVID-19 vaccines, neurological complications, Guillain-Barré syndrome, Bell's palsy, hemorrhagic stroke, BNT162b2, COVID-19 pandemic, vaccine safety
- MeSH terms
- Hemorrhagic Stroke, COVID-19, SARS-CoV-2, BNT162 Vaccine, ChAdOx1 nCoV-19, Adolescent, Adult, Aged, Aged, 80 and over, England, Female, Hospitalization, Humans, Male, Middle Aged, Nervous System Diseases, Scotland, Guillain-Barre Syndrome, Bell Palsy, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. https://app.cochat.ai/papers/10.1038/s41591-021-01556-7
- The paper
- Patone, M., Handunnetthi, L., Saatci, D., Pan, J., Katikireddi, S. V., Razvi, S., Hunt, D., Mei, X. W., Dixon, S., Zaccardi, F., Khunti, K., Watkinson, P., Coupland, C. A. C., Doidge, J., Harrison, D. A., Ravanan, R., Sheikh, A., Robertson, C., & Hippisley-Cox, J. (2021). Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nature Medicine. https://doi.org/10.1038/s41591-021-01556-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.